Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab Open-Label Extension in Generalized Myasthenia Gravis
NCT03896295Phase 2Terminated
- Sponsor
- Momenta Pharmaceuticals
- Start
- Aug 2019
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of nipocalimab in myasthenia gravis (MG), sponsored by Momenta Pharmaceuticals. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events up to 257 days, Number of Participants With Serious Adverse Events up to 257 days and 6 more. Started Aug 2019; status: terminated.
02
Drugs
nipocalimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT03896295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896295.